First case of breakthrough pulmonary Aspergillus niveus infection in a patient after allogeneic hematopoietic stem cell transplantation

Jutta Auberger; Cornelia Lass-Flörl; Johannes Clausen; Romuald Bellmann; Walter Buzina; Günther Gastl; David Nachbaur

doi:10.1016/j.diagmicrobio.2008.06.012

First case of breakthrough pulmonary Aspergillus niveus infection in a patient after allogeneic hematopoietic stem cell transplantation

Diagn Microbiol Infect Dis. 2008 Nov;62(3):336-9. doi: 10.1016/j.diagmicrobio.2008.06.012. Epub 2008 Aug 8.

Authors

Jutta Auberger¹, Cornelia Lass-Flörl, Johannes Clausen, Romuald Bellmann, Walter Buzina, Günther Gastl, David Nachbaur

Affiliation

¹ Clinical Division of Hematology and Oncology, Department of Internal Medicine, Innsbruck Medical University, A-6020 Innsbruck, Austria. jutta.auberger@i-med.ac.at

PMID: 18687556
DOI: 10.1016/j.diagmicrobio.2008.06.012

Abstract

Aspergillus niveus is a species uncommon in clinical samples, and to date, invasive fungal infections caused by this fungal pathogen have not been described. This is the 1st report on a pulmonary breakthrough aspergillosis caused by A. niveus in a 21-year-old woman after allogeneic hematopoietic stem cell transplantation for Fanconi anemia.

Publication types

Case Reports

MeSH terms

Amphotericin B / therapeutic use
Antifungal Agents / therapeutic use
Aspergillosis / drug therapy
Aspergillosis / microbiology*
Aspergillus / drug effects
Aspergillus / isolation & purification*
Bronchoalveolar Lavage Fluid / microbiology
Drug Resistance, Fungal
Fanconi Anemia / therapy
Fatal Outcome
Female
Hematopoietic Stem Cell Transplantation / adverse effects*
Humans
Lung Diseases, Fungal / drug therapy
Lung Diseases, Fungal / microbiology*
Pyrimidines / therapeutic use
Transplantation, Homologous
Triazoles / therapeutic use
Voriconazole
Young Adult

Substances

Antifungal Agents
Pyrimidines
Triazoles
Amphotericin B
Voriconazole